4,071 research outputs found
The landscape of the methodology in drug repurposing using human genomic data:a systematic review
The process of drug development is expensive and time-consuming. In contrast, drug repurposing can be introduced to clinical practice more quickly and at a reduced cost. Over the last decade, there has been a significant expansion of large biobanks that link genomic data to electronic health record (EHR) data, public availability of various databases containing biological and clinical information, and rapid development of novel methodologies and algorithms in integrating different sources of data. This review aims to provide a thorough summary of different strategies that utilize genomic data to seek drug-repositioning opportunities. We searched MEDLINE and EMBASE databases to identify eligible studies up until 1st May 2023, with a total of 102 studies finally included after two-step parallel screening. We summarized commonly used strategies for drug repurposing, including Mendelian randomization, multi-omic-based and network-based studies, and illustrated each strategy with examples, as well as the data sources implemented. By leveraging existing knowledge and infrastructure to expedite the drug discovery process and reduce costs, drug repurposing potentially identifies new therapeutic uses for approved drugs in a more efficient and targeted manner. However, technical challenges when integrating different types of data and biased or incomplete understanding of drug interactions are important hindrances that cannot be disregarded in the pursuit of identifying novel therapeutic applications. This review offers an overview of drug repurposing methodologies, providing valuable insights and guiding future directions for advancing drug repurposing studies
Systems pharmacology modeling: an approach to improving drug safety
Advances in systems biology in conjunction with the expansion in knowledge of drug effects and diseases present an unprecedented opportunity to extend traditional pharmacokinetic and pharmacodynamic modeling/analysis to conduct systems pharmacology modeling. Many drugs that cause liver injury and myopathies have been studied extensively. Mitochondrion‐centric systems pharmacology modeling is important since drug toxicity across a large number of pharmacological classes converges to mitochondrial injury and death. Approaches to systems pharmacology modeling of drug effects need to consider drug exposure, organelle and cellular phenotypes across all key cell types of human organs, organ‐specific clinical biomarkers/phenotypes, gene–drug interaction and immune responses. Systems modeling approaches, that leverage the knowledge base constructed from curating a selected list of drugs across a wide range of pharmacological classes, will provide a critically needed blueprint for making informed decisions to reduce the rate of attrition for drugs in development and increase the number of drugs with an acceptable benefit/risk ratio. Copyright © 2013 John Wiley & Sons, Ltd.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/102703/1/bdd1871.pd
Recommended from our members
Pharmacological risk factors associated with hospital readmission rates in a psychiatric cohort identified using prescriptome data mining
Background
Worldwide, over 14% of individuals hospitalized for psychiatric reasons have readmissions to hospitals within 30 days after discharge. Predicting patients at risk and leveraging accelerated interventions can reduce the rates of early readmission, a negative clinical outcome (i.e., a treatment failure) that affects the quality of life of patient. To implement individualized interventions, it is necessary to predict those individuals at highest risk for 30-day readmission. In this study, our aim was to conduct a data-driven investigation to find the pharmacological factors influencing 30-day all-cause, intra- and interdepartmental readmissions after an index psychiatric admission, using the compendium of prescription data (prescriptome) from electronic medical records (EMR).
Methods
The data scientists in the project received a deidentified database from the Mount Sinai Data Warehouse, which was used to perform all analyses. Data was stored in a secured MySQL database, normalized and indexed using a unique hexadecimal identifier associated with the data for psychiatric illness visits. We used Bayesian logistic regression models to evaluate the association of prescription data with 30-day readmission risk. We constructed individual models and compiled results after adjusting for covariates, including drug exposure, age, and gender. We also performed digital comorbidity survey using EMR data combined with the estimation of shared genetic architecture using genomic annotations to disease phenotypes.
Results
Using an automated, data-driven approach, we identified prescription medications, side effects (primary side effects), and drug-drug interaction-induced side effects (secondary side effects) associated with readmission risk in a cohort of 1275 patients using prescriptome analytics. In our study, we identified 28 drugs associated with risk for readmission among psychiatric patients. Based on prescription data, Pravastatin had the highest risk of readmission (OR = 13.10; 95% CI (2.82, 60.8)). We also identified enrichment of primary side effects (n = 4006) and secondary side effects (n = 36) induced by prescription drugs in the subset of readmitted patients (n = 89) compared to the non-readmitted subgroup (n = 1186). Digital comorbidity analyses and shared genetic analyses further reveals that cardiovascular disease and psychiatric conditions are comorbid and share functional gene modules (cardiomyopathy and anxiety disorder: shared genes (n = 37; P = 1.06815E-06)).
Conclusions
Large scale prescriptome data is now available from EMRs and accessible for analytics that could improve healthcare outcomes. Such analyses could also drive hypothesis and data-driven research. In this study, we explored the utility of prescriptome data to identify factors driving readmission in a psychiatric cohort. Converging digital health data from EMRs and systems biology investigations reveal a subset of patient populations that have significant comorbidities with cardiovascular diseases are more likely to be readmitted. Further, the genetic architecture of psychiatric illness also suggests overlap with cardiovascular diseases. In summary, assessment of medications, side effects, and drug-drug interactions in a clinical setting as well as genomic information using a data mining approach could help to find factors that could help to lower readmission rates in patients with mental illness
Graph Representation Learning in Biomedicine
Biomedical networks are universal descriptors of systems of interacting
elements, from protein interactions to disease networks, all the way to
healthcare systems and scientific knowledge. With the remarkable success of
representation learning in providing powerful predictions and insights, we have
witnessed a rapid expansion of representation learning techniques into
modeling, analyzing, and learning with such networks. In this review, we put
forward an observation that long-standing principles of networks in biology and
medicine -- while often unspoken in machine learning research -- can provide
the conceptual grounding for representation learning, explain its current
successes and limitations, and inform future advances. We synthesize a spectrum
of algorithmic approaches that, at their core, leverage graph topology to embed
networks into compact vector spaces, and capture the breadth of ways in which
representation learning is proving useful. Areas of profound impact include
identifying variants underlying complex traits, disentangling behaviors of
single cells and their effects on health, assisting in diagnosis and treatment
of patients, and developing safe and effective medicines
Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance.
Mycobacterium tuberculosis is a serious human pathogen threat exhibiting complex evolution of antimicrobial resistance (AMR). Accordingly, the many publicly available datasets describing its AMR characteristics demand disparate data-type analyses. Here, we develop a reference strain-agnostic computational platform that uses machine learning approaches, complemented by both genetic interaction analysis and 3D structural mutation-mapping, to identify signatures of AMR evolution to 13 antibiotics. This platform is applied to 1595 sequenced strains to yield four key results. First, a pan-genome analysis shows that M. tuberculosis is highly conserved with sequenced variation concentrated in PE/PPE/PGRS genes. Second, the platform corroborates 33 genes known to confer resistance and identifies 24 new genetic signatures of AMR. Third, 97 epistatic interactions across 10 resistance classes are revealed. Fourth, detailed structural analysis of these genes yields mechanistic bases for their selection. The platform can be used to study other human pathogens
Supporting Regularized Logistic Regression Privately and Efficiently
As one of the most popular statistical and machine learning models, logistic
regression with regularization has found wide adoption in biomedicine, social
sciences, information technology, and so on. These domains often involve data
of human subjects that are contingent upon strict privacy regulations.
Increasing concerns over data privacy make it more and more difficult to
coordinate and conduct large-scale collaborative studies, which typically rely
on cross-institution data sharing and joint analysis. Our work here focuses on
safeguarding regularized logistic regression, a widely-used machine learning
model in various disciplines while at the same time has not been investigated
from a data security and privacy perspective. We consider a common use scenario
of multi-institution collaborative studies, such as in the form of research
consortia or networks as widely seen in genetics, epidemiology, social
sciences, etc. To make our privacy-enhancing solution practical, we demonstrate
a non-conventional and computationally efficient method leveraging distributing
computing and strong cryptography to provide comprehensive protection over
individual-level and summary data. Extensive empirical evaluation on several
studies validated the privacy guarantees, efficiency and scalability of our
proposal. We also discuss the practical implications of our solution for
large-scale studies and applications from various disciplines, including
genetic and biomedical studies, smart grid, network analysis, etc
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis
In the dynamic landscape of drug discovery, Computer-Aided Drug Design (CADD) emerges as a transformative force, bridging the realms of biology and technology. This paper overviews CADDs historical evolution, categorization into structure-based and ligand-based approaches, and its crucial role in rationalizing and expediting drug discovery. As CADD advances, incorporating diverse biological data and ensuring data privacy become paramount. Challenges persist, demanding the optimization of algorithms and robust ethical frameworks. Integrating Machine Learning and Artificial Intelligence amplifies CADDs predictive capabilities, yet ethical considerations and scalability challenges linger. Collaborative efforts and global initiatives, exemplified by platforms like Open-Source Malaria, underscore the democratization of drug discovery. The convergence of CADD with personalized medicine offers tailored therapeutic solutions, though ethical dilemmas and accessibility concerns must be navigated. Emerging technologies like quantum computing, immersive technologies, and green chemistry promise to redefine the future of CADD. The trajectory of CADD, marked by rapid advancements, anticipates challenges in ensuring accuracy, addressing biases in AI, and incorporating sustainability metrics. This paper concludes by highlighting the need for proactive measures in navigating the ethical, technological, and educational frontiers of CADD to shape a healthier, brighter future in drug discovery
Large–scale data–driven network analysis of human–plasmodium falciparum interactome: extracting essential targets and processes for malaria drug discovery
Background: Plasmodium falciparum malaria is an infectious disease considered to have great impact on public health due to its associated high mortality rates especially in sub Saharan Africa. Falciparum drugresistant strains, notably, to chloroquine and sulfadoxine-pyrimethamine in Africa is traced mainly to Southeast Asia where artemisinin resistance rate is increasing. Although careful surveillance to monitor the emergence and spread of artemisinin-resistant parasite strains in Africa is on-going, research into new drugs, particularly, for African populations, is critical since there is no replaceable drug for artemisinin combination therapies (ACTs) yet. Objective: The overall objective of this study is to identify potential protein targets through host–pathogen protein–protein functional interaction network analysis to understand the underlying mechanisms of drug failure and identify those essential targets that can play their role in predicting potential drug candidates specific to the African populations through a protein-based approach of both host and Plasmodium falciparum genomic analysis. Methods: We leveraged malaria-specific genome wide association study summary statistics data obtained from Gambia, Kenya and Malawi populations, Plasmodium falciparum selective pressure variants and functional datasets (protein sequences, interologs, host-pathogen intra-organism and host-pathogen inter-organism protein-protein interactions (PPIs)) from various sources (STRING, Reactome, HPID, Uniprot, IntAct and literature) to construct overlapping functional network for both host and pathogen. Developed algorithms and a large-scale data-driven computational framework were used in this study to analyze the datasets and the constructed networks to identify densely connected subnetworks or hubs essential for network stability and integrity. The host-pathogen network was analyzed to elucidate the influence of parasite candidate key proteins within the network and predict possible resistant pathways due to host-pathogen candidate key protein interactions. We performed biological and pathway enrichment analysis on critical proteins identified to elucidate their functions. In order to leverage disease-target-drug relationships to identify potential repurposable already approved drug candidates that could be used to treat malaria, pharmaceutical datasets from drug bank were explored using semantic similarity approach based of target–associated biological processes Results: About 600,000 significant SNPs (p-value< 0.05) from the summary statistics data were mapped to their associated genes, and we identified 79 human-associated malaria genes. The assembled parasite network comprised of 8 clusters containing 799 functional interactions between 155 reviewed proteins of which 5 clusters contained 43 key proteins (selective variants) and 2 clusters contained 2 candidate key proteins(key proteins characterized by high centrality measure), C6KTB7 and C6KTD2. The human network comprised of 32 clusters containing 4,133,136 interactions between 20,329 unique reviewed proteins of which 7 clusters contained 760 key proteins and 2 clusters contained 6 significant human malaria-associated candidate key proteins or genes P22301 (IL10), P05362 (ICAM1), P01375 (TNF), P30480 (HLA-B), P16284 (PECAM1), O00206 (TLR4). The generated host-pathogen network comprised of 31,512 functional interactions between 8,023 host and pathogen proteins. We also explored the association of pfk13 gene within the host-pathogen. We observed that pfk13 cluster with host kelch–like proteins and other regulatory genes but no direct association with our identified host candidate key malaria targets. We implemented semantic similarity based approach complemented by Kappa and Jaccard statistical measure to identify 115 malaria–similar diseases and 26 potential repurposable drug hits that can be 3 appropriated experimentally for malaria treatment. Conclusion: In this study, we reviewed existing antimalarial drugs and resistance–associated variants contributing to the diminished sensitivity of antimalarials, especially chloroquine, sulfadoxine-pyrimethamine and artemisinin combination therapy within the African population. We also described various computational techniques implemented in predicting drug targets and leads in drug research. In our data analysis, we showed that possible mechanisms of resistance to artemisinin in Africa may arise from the combinatorial effects of many resistant genes to chloroquine and sulfadoxine–pyrimethamine. We investigated the role of pfk13 within the host–pathogen network. We predicted key targets that have been proposed to be essential for malaria drug and vaccine development through structural and functional analysis of host and pathogen function networks. Based on our analysis, we propose these targets as essential co-targets for combinatorial malaria drug discovery
Leveraging FAERS and Big Data Analytics with Machine Learning for Advanced Healthcare Solutions
This research study explores the potential of leveraging the FDA Adverse Event Reporting System (FAERS), combined with big data analytics and machine learning techniques, to enhance healthcare solutions. FAERS serves as a comprehensive database maintained by the U.S. Food and Drug Administration (FDA), encompassing reports of adverse events, medication errors, and product quality issues associated with diverse drugs and therapeutic interventions.By harnessing the power of big data analytics applied to the vast information within FAERS, healthcare professionals and researchers gain valuable insights into drug safety, discover potential adverse reactions, and uncover patterns that may not have been discernible through traditional methods. Particularly, machine learning plays a pivotal role in processing and analyzing this extensive dataset, enabling the extraction of meaningful patterns and prediction of adverse events.The findings of this study demonstrate various ways in which FAERS, big data analytics, and machine learning can be leveraged to provide advanced healthcare solutions. Machine learning algorithms trained on FAERS data can effectively identify early signals of adverse events associated with specific drugs or treatments, allowing for prompt detection and appropriate actions.Big data analytics applied to FAERS data facilitate pharmacovigilance and drug safety monitoring. Machine learning models automatically classify and analyze adverse event reports, efficiently flagging potential safety concerns and identifying emerging trends.The integration of FAERS data with big data analytics and machine learning enables signal detection and causality assessment. This approach aids in the identification of signals that suggest a causal relationship between drugs and adverse events, thereby enhancing the assessment of drug safety.By analyzing FAERS data in conjunction with patient-specific information, machine learning models can assist in identifying patient subgroups that are more susceptible to adverse events. This information is instrumental in personalizing treatment plans and optimizing medication choices, ultimately leading to improved patient outcomes.The combination of FAERS data with other biomedical information offers insights into potential new uses or indications for existing drugs. Machine learning algorithms analyze the integrated data, identifying patterns and making predictions about the efficacy and safety of repurposing existing drugs for new applications.The implementation of FAERS, big data analytics, and machine learning in advanced healthcare solutions necessitates meticulous consideration of data privacy, security, and ethical implications. Safeguarding patient privacy and ensuring responsible data use through anonymization techniques and appropriate data governance are paramount.The integration of FAERS, big data analytics, and machine learning holds immense potential in advancing healthcare solutions, enhancing patient safety, and optimizing medical interventions. The findings of this study demonstrate the multifaceted benefits that can be derived from leveraging these technologies, paving the way for a more efficient and effective healthcare ecosystem
- …